4th Nov 2015 10:42
LONDON (Alliance News) - Gene and cell therapy company Oxford BioMedica PLC on Wednesday said it has continued to make progress on its strategy.
The company said the expansion of its manufacturing sites are progressing well, and it is working on developing its OXB-102 and OXB-202 products towards their next clinical trials, due to start in 2016.
"Our revenue and other income is now beginning to grow in line with our expectations with July to October being well ahead of the first four months of the year," added John Dawson, Oxford BioMedica's chief executive.
Shares in the company were up 1.1% to 8.0384 pence on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica